Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
@PL75
Theres a few on that website, but this is the correct one being saliva:
https://shop.bioservuk.com/product/rapid-responsetm-covid-19-saliva-rapid-antigen-test/
Like I say Orph are only targeting large corporations so won't even touch who Avacta will be supplying for the mass testing program. Really nothing to worry about.
If anything it proves that saliva does in fact work and I'm in the camp that Avacta are still working on both saliva and nasal. Nasal being for the Gov Sovereign test where we're involved in the consortium. And saliva possibly being under Cytivas name, given that in Abingdon Health's releases, first they stated Avacta, then they said last week that they are working with an international partner (Could it be Cytiva?).
Going to be a very interesting next couple of weeks when Boris lays out his grand plan to get the economy going again. A nice article in the Mail today about testing in the workplace
Not sure it is competition Momiman. Like you I'm heavily invested in both Avacta and Orph but theres a big difference here, that the test is selling for £250 for 25 tests so £10 a pop and its only for healthcare professionals, so they're targeting the big private companies as previously said the likes of JP Morgan, CitiBank etc. Given that it is saliva and the spec/sens is very good it will get bought in the masses, but remember that the demand is so big that theres enough room for all.
Avacta will be far under £10 a test, given that on the tenders the Gov didn't want anything over £6 a test. Also that Affimers are far superior than everything else on the market that we're led to believe. Fully believe that given David Wilsons & Alastairs comments previously + Han**** / Boris and the documentation that has come out, that Avacta are working very closely with the Government to produce a sovereign test. The vaccine developments with the disagreement about supply with the EU will only intensify the need for a UK supply.
Theres plenty of room for both in the market and should see some serious upside in both.
Might be easier if you think all the way back to Quotient partnership. We have everything in place from the logistics of providing covid tests already.
These tests are only authorised for use by a healthcare professional so we literally have everything in place already for this new partnership.
Think back to when we were targeting JP Morgan, CitiBank, City of London, Sainsbury's, Tesco's etc.
So yes it seems almost nailed on that we will be using that for these antigen tests for UK and Ireland. Massive market and will be good margins.
Looks like BioServ produce the reagents, BTNK are the manufacturer and then looks like we're going to be selling and distributing. Which makes sense given we are already doing Quotient so we have the network/contacts and logistics in place.
£250 for 25 tests so £10 a pop. I'm heavily invested in a couple of other testing stocks, so really shocked to see this test almost come out of nowhere. Really really impressive sens/spec for a rapid test (10mins). Far more beneficial than PCR and the lab tests. Even a tiny % of the profits on a test like this COULD be absolutely transformational. Honestly looks like one of the best tests out there right now, many large companies gave up with saliva testing (lateral flow) as it was too hard to crack, and the likes of Innova have shocking sens/spec %s.
https://shop.bioservuk.com/product/rapid-responsetm-covid-19-saliva-rapid-antigen-test/
The Orph story just keeps getting better and better. Definitely aiming for private companies based on the cost per test being £10. That sens/spec % is incredible though if you compare it to the rest on the market. And most importantly its saliva & detects asymptomatic too, isnt one better on the market currently thats a lateral flow test!
I wont share the email on a public BB. However I expressed concerns about talking down the share price as such, and the lack of updates / about the price being stagnant on relatively low volume. One thing that I found curious was he received a lot of complaints that he was doing too many presentations, but he will pick them up and get more lined up than the 3 currently listed. And that of course ties in with the exciting weeks and months ahead. He and Amanda also replied to a couple other emails this afternoon. Anyone who knows me from the other group will vouch for me and that its 100% legit.
Agree with Demon. I believe they are happy slicing a certain % at X price and no lower than X price. Noticed that theres generally no big sell orders under 25p and earlier today both CFEP and BERB flipped from the ask to the bid. So thats positive.. However as we know say we rise to 26p there might be some slicing again, but there also might not be. All a part of the game I guess!
What I will say is Cathal addressed my concerns today (the very few I had) and I'm very pleased and looking forward to seeing what happens over the next few weeks!
Great find Trader_3. Actually very interested in that wording Open Orphan and Codegenix collab... Just thinking that PrepBio has been left off Conserv yet flu-v and ags-v is shown... So Prep could be the perfect fit for Codagenix vaccine... More clarification needed from Cathal, a question i'll be asking for the presentation.
So much going on right now, will be impossible for Cathal to keep a lid on the share price going forward, just waiting for that big pop upwards.
Well considering we don't know how much they're scaling up to, could be in excess of the 3m they said they can make, add in ODX 2m, then BBI etc? Gov want 2m a day so very plausible that there could be excess capacity here by the time rollout is due.
Abingdon continues to invest further in its automated manufacturing capacity and is planning to expand both its York and Doncaster sites. The Company expects a number of key items of automated assembly equipment to come on-line over the coming months and these will increase significantly its automated manufacturing capacity.
Abingdon is pleased to report that one of its international contract service customers has received a CE mark for professional use for its COVID-19 lateral flow antigen test. The Company is now working closely with this partner regarding the scale-up of manufacturing to meet anticipated demand for this test. Furthermore, the Company continues to work with a number of other COVID-19 antigen test contract service partners with products in development.
Looking very good so far. 51 trades so far this morning, 48 of them being buys, volume looking good and ticked up nicely. Hopefully can keep this up, been a couple months since last seen this buying pressure
Theres additional tenders posted as well:
Provision of Facilities for Human Challenge Characterisation Study.
£3.6m.
https://bidstats.uk/tenders/2021/W03/743374991
Clinical sponsorship of the Human Challenge Characterisation Study.
£1.8m
https://bidstats.uk/tenders/2021/W03/743374989
Well one thing I'd say is you should care very much about new investors, they bring in new volume that's needed to shift any sells, in turn creates a higher share price as their entry is higher which helps create a higher base for us all which helps your investment now and your decision making.
Timelines get delayed for things out of their control, Imutex looks like the SPAC will be much more valuable than previously expected. MRHA have their own timeline, completely out of our hands even though the last two days does seem like a switch has been flipped and Orph are ramping things up massively, so maybe a green light has been given but just waiting on the publication from MRHA as it can't come from Orph first. That in turn allows the deals to be signed and contracts rolled out consistently and then opens up the wearables for higher sums compared to non covid.
Keep positive, this is only the start!
Northseatiger1, as I just said it's an RNS REACH, very different to an RNS. Cathal has done this 3 times before I believe all prior to the main news landing.
Take it how you like but this is nothing but positive imho.
Should being in new volume as not everyone is glued to these bulletin boards for updates, so targets a huge audience.
Join the dots together and you start to see what's unfolding with the new screening centres, lots of job vacancies popping up, social media ramping up all in the space of a day.
Well it's an RNS REACH, and not an actual RNS.
This is simply to give knowledge to the market and it's definitely a tactic to try and get some volume going to bring in some buys.
Really rate that Cathal has done this tbh and also it's a very good article.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
Cathal interview from last year makes me believe that there will be an additional UK facility for the covid challenge studies and not just the Royal Free.
"We wont be able to do it in a 24 bed clinic, we need 100 beds, we're in active discussions and seeking an alternative facility in addition to our 24 beds and will have somewhere with 100 beds in quarantine and will have that under temporary arrangement for 1-2 years, we dont need it long term, absolutely we're scaling up. That will be a offsite 3rd party facility that we will have use of.
All the vaccine developers are in a rush, so we'll be charging a booking fee up front for a slot, we can probably run 2 in parralel, and its a scarce resource so we have something that they want"
Then skip forward to today with his additional comments with DT. Now being able to screen 620+ people a week in the UK between London and Manchester, huge number, makes me believe it can't be just for Hvivo or the Royal Free which would be approx 40 beds over a few weeks?
"These new volunteer recruitment centres are extremely cost effective and will crucially also enable us to have the scale to run a third quarantine facility which will allow further upside in revenue"
Then I believe our 4th facility as such would be SGS unused facility which potentially could be for the new challenge models that are being developed, malaria etc.
Exactly.
He also says about an update about a 3rd facility soon on it... Does anyone remember when Cathal said about a 3rd facility for the covid19 trials being in the UK and them renting it out? Would be able to have over 100 patients on a pop up facility and then of course the Royal Free.
To date we thought that the 3rd facility would be abroad.. Why would they be expanding screening centres in the UK if its only for the Hvivo facility?
Simply has to be screening for the Royal Free imo + another facility. Just look at the numbers they are talking about being able to screen in the RNS. 520 screening in London and 100+ in Manchester...
They wouldnt screen in the UK and say use then SGS facility in Belgium which would require volunteers to travel abroad.
"These new volunteer recruitment centres are extremely cost effective and will crucially also enable us to have the scale to run a third quarantine facility which will allow further upside in revenue"
Which leads me to think given they'd be in strong dialouge with MRHA that they must be very confident of approval here
“We are off to a fighting start in 2021 with today’s announcement that we are adding two new volunteer recruitment screening centres for our human challenge trials. The current pandemic has forced many businesses to close and we are delighted to provide another use for these spaces through opening both of these volunteer recruitment centres.
Adding both volunteer recruitment centres is also a key part in us scaling up to deliver our contracted work in 2021 which is sure to be a record year of both revenues and profits for the company. These new volunteer recruitment centres are extremely cost effective and will crucially also enable us to have the scale to run a third quarantine facility which will allow further upside in revenues. On that note, the company continues to examine additional quarantine facilities options as the company’s existing 24 bed state of the art quarantine facility in East London and its quarantine ward at the Royal Free Hospital are fully booked until year end and the company’s hope is to have an update to the market on the third quarantine facility shortly.
The pandemic has unlocked a decade of exponential spend on developing vaccine and antivirals and a third facility and today’s extra volunteer recruitment capacity will allow Open Orphan to take advantage of its unique position as the world leader in testing both vaccines and antivirals using human viral challenge studies in what is sure to be one of the most fast growing and lucrative niches of the pharma industry over the next decade and beyond. “
https://www.***************************/open-orphan-expands-volunteer-recruitment-centres-for-human-challenge-trials/412954530
Found a couple others,
Declan Monaghan - CFO at Conserv
Olga Pleguezuelos CSO at Conserv
Both CFO & CSO at SEEK.
Also links between Conserv and Optimum Strategic Communications.
The ball is clearly rolling and picking up speed now
Adrian Wildfire posted this last week. Apologises if anyone posted it before, but certainly seems rather positive regarding the challenge studies.
According to that they've already repurposed the BSL3 containment ward from using it for Covid patients, to now the worlds first COVID-19-specific challenge unit.
Very good read anyway, just need some patience here and to ignore the daily swings as the end price will always be the same, just some short term noise we have right now which gives some bargain top up opportunities.
https://www.sciencedirect.com/science/article/pii/S1359644621000027?via%3Dihub